2022 NYSAM Annual Virtual Meeting

Dear NYSAM Members,

Our upcoming annual meeting will be held virtually Feb. 11^th and Feb. 12^th!
See below for more details on the daily agendas. 

AMA Credit Designation StatementThis conference has been approved for
CME by ASAM (anticipated to be 8.5 CME hours

This activity has been approved for AMA PRA Category 1 Credit™
ASAM/NYSAM Member Registration Fee: $100
Non-member Registration Fee: $150
Students/Residents/Fellows Fee: FREE
Register Here!

Friday, February 11th, 1 pm – 5 pm
The Annual Public Policy Day
Scheduled topics include: Overdose Prevention Centers, Updating Methadone Regulations, Legislative Updates, and New ASAM Policy Statements

Saturday, February 12th, 8 am – 2:30 pm 
The Annual Scientific and Treatment Conference 
Scheduled topics include: Clinical Case Presentations; History of Office-based Methadone Maintenance in NYS; Panel Discussion on Outcomes Data for Buprenorphine Prescribing via Telemedicine; Panel on Buprenorphine Microdosing Strategies to Avoid Precipitated OWS (opioid withdrawal syndrome) in the Era of Fentanyl and Fentanyl Analogues; Toxicology Panel

Annual Policy Day Agenda
Friday, February 11^th 

Session 1: “Addiction treatment in New York State in 2022”  

Objectives: 

1. Learners will list at least 3 changes to New York State law that passed in 2021
2. Learners will describe at least 1 priority for OASAS in 2022
3. Learners will describe at least 1 policy change that could reduce overdose deaths

Speakers: 

Senator Gustavo Rivera, New York State’s 33^rd Senate District, Chairman of Committee on Health
Chinazo O. Cunningham, MD MS, Commissioner, New York State Office of Addiction Services and Supports (OASAS)
Lisa Skill, MS MCHES, Office of Drug User Health, New York State Department of Health-AIDS Institute
Narelle Ellendon, RN, Office of Drug User Health, New York State Department of Health-AIDS Institute

Session 2: “Overdose Prevention Centers – current challenges and opportunities” 

Objectives: 

1. Learners will describe the services provided at overdose prevention centers
2. Learners will describe at least one study that has examined the impact of overdose prevention centers on health outcomes
3. Learners will propose at least one initiative in which addiction medicine specialists could collaborate with overdose prevention centers

Speakers: 

Sam Rivera, Executive Director, On Point NYC (New York Harm Reduction Educators and Washington Heights CORNER Project)
Brandon Marshall, PhD, Associate Professor, Department of Epidemiology, Brown University School of Public Health
Aaron D. Fox, MD MS, Associate Professor, Department of Medicine, Albert Einstein College of Medicine-Montefiore Medical Center

Session 3: “Increasing Access to Methadone Treatment” 

Objectives: 

1. Learners will describe the regulatory framework for methadone treatment
2. Learners will describe the impact of methadone regulatory changes during the COVID-19 pandemic
3. Learners will propose at least one alternative model to current opioid treatment programs that could provide methadone treatment

Speakers: 

Paul Joudrey, MD MS, Assistant Professor, General Internal Medicine, Yale School of Medicine
Shadi Nahvi, MD MS, Associate Professor of Medicine, Department of Medicine, Albert Einstein College of Medicine-Montefiore Medical Center
David Frank, PhD, Postdoctoral Fellow, Rory Meyers College of Nursing, New York University
Celyn Sai Lynn Ng, MPharm, MPH, New York State Office of Addiction Services and Supports

Session 1: “Policy priorities for 2022 and beyond” 

Objectives:

1. Learners will list at least 3 changes to New York State law that passed in 2021
2. Learners will describe at least 1 policy priority for OASAS in 2022
3. Learners will describe at least 1 policy change that could reduce overdose deaths

Speakers:

Senator Gustavo Rivera, New York State’s 33^rd Senate District, Chairman of Committee on Health
Chinazo O. Cunningham, MD MS, Commissioner, New York State Office of Addiction Services and Supports (OASAS)
Lisa Skill, Office of Drug User Health, MS MCHES, New York State Department of Health-AIDS Institute

Session 2: “Overdose Prevention Centers – current challenges and opportunities”

Objectives:

1. Learners will describe the services provided at overdose prevention centers
2. Learners will describe at least one study that has examined the impact of overdose prevention centers on health outcomes
3. Learners will propose at least one initiative in which addiction medicine specialists could collaborate with overdose prevention centers

Speakers:

Sam Rivera, Executive Director, On Point NYC (New York Harm Reduction Educators and Washington Heights CORNER Project)
Brandon Marshall, PhD, Associate Professor, Department of Epidemiology, Brown University School of Public Health
Aaron D. Fox, MD MS, Associate Professor, Department of Medicine, Albert Einstein College of Medicine-Montefiore Medical Center

Session 3: “Increasing Access to Methadone Treatment”

Objectives:

1. Learners will describe the regulatory framework for methadone treatment
2. Learners will describe the impact of methadone regulatory changes during the COVID-19 pandemic
3. Learners will propose at least one alternative model to current opioid treatment programs that could provide methadone treatment

Speakers:

Paul Joudrey, MD MS, Assistant Professor, General Internal Medicine, Yale School of Medicine
Shadi Nahvi, MD MS, Associate Professor of Medicine, Department of Medicine, Albert Einstein College of Medicine-Montefiore Medical
Center
Patient Representative, Methadone Treatment 

Annual Scientific and Treatment Conference Agenda
Saturday, February 12^th 

Session 1: “Interesting Addiction Medicine Cases” 

Objectives:

1. Learners will describe the presentation and treatment of a “Fast In—Fast Out” drug
2. Learners will describe when is it safe to start IM Depot Naltrexone: the Toxicology Dilemma
3. Learners will describe the limitations of urine toxicology

Speaker:

Edwin A. Salsitz, MD, DFASAM, Associate Clinical Professor of Psychiatry at the Mount Sinai School of Medicine

Session 2: “History of Office-based Methadone Maintenance in NYS” 

Objectives: 

1. Learners will describe the History and Evolution of OUD Treatment
2. Learners will describe the Intended and Unintended Consequences of the Methadone Clinic System
3. Learners will describe Methadone Medical Maintenance: An Office Based Treatment Paradigm
4. Learners will describe the Current State of Methadone OBOT (Office-based Opioid Treatment)

Speaker:

Edwin A. Salsitz, MD, DFASAM, Associate Clinical Professor of Psychiatry at the Mount Sinai School of Medicine

Session 3: “Panel Discussion on Outcomes Data for Buprenorphine Prescribing Via Telemedicine”

Panelist #1:

Title: “Using Telemedicine to Continue Buprenorphine Prescribing in Primary Care”

Objectives: 

1. Learners will describe how a New York City primary care-based buprenorphine treatment program transitioned to telemedicine during the COVID-19 pandemic
2. Learners will describe strategies for implementing telemedicine-based buprenorphine prescribing in primary care
3. Learners will describe outcomes for buprenorphine prescribing using telemedicine in primary care

Speaker: 

Eric C. Wood, MD, Instructor, Department of Medicine, Division of General Internal Medicine
Icahn School of Medicine at Mount Sinai

Panelist #2:

Title: “Panel on Outcomes Data on Buprenorphine Prescribing via Telemedicine”

Objectives:

1. Learners will gain a better understanding of why Telehealth is an effective tool in treating people with OUD (opioid use disorder)
2. Learners will gain an understanding of how Telehealth can affect a region in which access to care may not be available
3. Learners will gain an understanding of the demographics of who might benefit from telephonic (audio only) care over video care 

Speaker: 

Justine L. Waldman, MD, FACEP, CEO/Founder, Reach Medical, Ithaca, NY

Panelist #3:

Title: “Virtual Buprenorphine Care: A low threshold virtual buprenorphine clinic” 

Objectives:

1. Learners will describe how telemedicine expands access to care
2. Learners will describe how to maintain a safe low threshold, harm reduction virtual clinic
3. Learners will describe how to make a warm virtual hand off and follow up

Speaker: 

Daniel Schatz, MD, MSc, Adjunct Assistant Professor of Population Health at NYU, Director of Program and Policy at the Office of Behavioral Health, Health + Hospitals

Session 4: “Panel on Buprenorphine Microdosing Strategies to Avoid Precipitated OWS (opioid withdrawal syndrome) in the Era of Fentanyl and Fentanyl Analogues”

Objectives:

TBD

Speakers:

Shawn Matthew Cohen, MD, Addiction Medicine Fellow, Yale University, Fellow, National Clinical Scholars Program, Yale University
Ashish Prakash Thakrar, MD, Fellow, National Clinical Scholars Program, University of Pennsylvania
Joji Suzuki, MD, Assistant Professor of Psychiatry, Harvard Medical School, Site Director, Boston Children’s Hospital Addiction Medicine Fellowship
Saeed Ahmed, MD, Medical Director, West Ridge Center, RRMC VT

Session 5: “The NYSAM Toxicology Panel:  The 2022 Update on Synthetic Drugs”

An illustrative synthetic cannabinoid case

“Pressed Xanax” and the state of the novel benzodiazepine market

Evolution of the Novel Synthetic Opioid (NSO) market and the emergency of the ‘-nitazenes’

Objectives:

1. Learners will describe current trends in novel psychoactive substances in the United State related to designer benzodiazepines
2. Learners will describe synthetic cannabinoid intoxication and withdrawal
3. Learners will describe how the use of social media search technologies can help determine emerging drug use patterns and threats.
4. Learners will describe the basic pharmacology of the benzimadole derived opioids and their emergency on the illicit drug market (e.g., istotonitazene, etonitazene, metonitazene).

Speakers:

Moderator: 

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM Moderator
President-New York Society of Addiction Medicine & Director of Addiction Toxicology and the Toxicology Consult Service, Associate Professor of Emergency Medicine at the University of Rochester Medical Center, Rochester, New York

Panelists: 

Jeffrey Brent, MD, PhD, Distinguished Clinical Professor of Medicine and Emergency Medicine, University of Colorado School of Medicine and the Colorado School of Public Health, Denver, CO
Barry K Logan, PhD, FABFT, Executive Director, Center for Forensic Science Research and Education; Chief Scientist, NMS Labs, Willow Grove, PA
Alaina Steck, MD, Assistant Professor of Emergency Medicine at Grady Memorial Hospital and the Medical Director of the Grady Medication-Assisted Opioid Treatment (MAOT) Clinic, Atlanta, GA
Stephanie Weiss, MD, PhD, Medically Accountable Investigator, Translational Addiction Medicine Branch, National Institute on Drug Abuse, National Institutes of Health
Paul Wax, MD, FACMT, Executive Director of the American College of Medical Toxicology (ACMT), Phoenix, AZ